Earnings Call Summary | AVACTA GROUP PLC(AVCTF.US) Q4 2023 Earnings Conference
Earnings Call Summary | AVACTA GROUP PLC(AVCTF.US) Q4 2023 Earnings Conference
The following is a summary of the Avacta Group PLC (AVCTF) Q4 2023 Earnings Call Transcript:
以下是Avacta Group PLC（AVCTF）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Avacta reported a revenue growth up to £23 million, largely due to acquisitions of Launch and Coris.
The company saw an operating loss of £28 million, slightly lower than the previous year, and a loss per share of just over 9p.
Growth was significant in the Diagnostics provision from £4 million revenue to £21 million, reducing the group EBITDA loss to just over £1 million.
The Therapeutics segment experienced a greater loss of £13 million in adjusted EBITDA compared to the previous year due to research costs for clinical programs.
-Avacta anticipates continued profitability from its Diagnostics division, expecting to be EBITDA positive in H2 2024 and cash generative by 2025
Avacta報告收入增長高達2300萬英鎊，這主要歸因於對Launch和Coris的收購。
該公司的營業虧損爲2,800萬英鎊，略低於上年，每股虧損略高於9便士。
診斷撥款大幅增長，收入從400萬英鎊增至2100萬英鎊，使集團息稅折舊攤銷前利潤虧損降至略高於100萬英鎊。
由於臨床項目的研究成本，治療板塊調整後的息稅折舊攤銷前利潤與去年相比損失了1300萬英鎊。
-Avacta預計其診斷部門將持續盈利，預計2024年下半年的息稅折舊攤銷前利潤將爲正數，到2025年將產生現金
Business Progress:
業務進展：
Avacta's growth has been substantial due to the successful integration of Launch and Coris, fueling its continued investment in the Therapeutics segment.
The company's financial planning looks sound with cash on hand expected to last till early 2026.
The AVA6000 study provides promising evidence for Avacta's pre|CISION platform, showing high concentrations of anticancer drugs in tumor microenvironments.
Significant antitumor activity was recorded in some patients and there have been improvements in safety and toxicity.
The company plans to establish the Phase II dosage for AVA6000, begin expansion cohorts in H2 2024, and release an updated pipeline of Avacta Therapeutics' assets in late 2024.
由於Launch和Coris的成功整合，Avacta實現了可觀的增長，這推動了其對治療領域的持續投資。
該公司的財務規劃看起來不錯，手頭現金預計將持續到2026年初。
AVA6000 研究爲 Avacta 的 pre|Cision 平台提供了令人鼓舞的證據，顯示腫瘤微環境中抗癌藥物濃度很高。
在一些患者中記錄了顯著的抗腫瘤活性，安全性和毒性都有所改善。
該公司計劃確定 AVA6000 的二期劑量，在 2024 年下半年開始擴張隊伍，並在 2024 年底發佈最新的 Avacta Therapeutics 資產管道。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。